Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03562975 · ClinicalTrials.gov registry record
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
A clinical trial, sponsored by University of South Florida.
- Completed
- Registry status
- 18
- Enrollment target
NCT03562975: Completed study, sponsored by University of South Florida.
NCT03562975 is a clinical trial that has completed, run by University of South Florida. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03562975 has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
Study Summary
The investigators are measuring the effectiveness of Ocrevus™ in helping patients with hand or arm weakness, especially if posed by a more advanced MS patient than those included in the clinical trials.
Primary Outcome
The TEMPA is designed to assess the capabilities and limitations of upper limb function and consists of 9 tasks that mimic tasks of daily living that include picking up a jar, taking a spoonful of coffee from a jar, pouring water from a pitcher, handling coins, writing on an envelope and opening a pill container, tying a scarf around one's neck, shuffle and deal playing cards, and picking up and moving small objects. Each task is assessed by a rater by measuring speed of execution (seconds) and
Interventions
- DRUG Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-07-23 |
| Est. Completion | 2023-01-11 |
What the finished NCT03562975 record still lists
NCT03562975 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT03562975 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03562975 about?
NCT03562975 is a clinical study titled "Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus". The investigators are measuring the effectiveness of Ocrevus™ in helping patients with hand or arm weakness, especially if posed by a more advanced MS patient than those included in the clinical trials.
What is the current status of trial NCT03562975?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2018-07-23. Estimated completion is 2023-01-11.
What interventions are being tested in trial NCT03562975?
The interventions under investigation include: Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT03562975?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI